Guard Therapeutics AB (publ.) today announces that the company has received an Intention to Grant notice from the European Patent Office (EPO) for a patent application concerning its biological investigational drug ROSgard as a product, including its medical use. The next step in the process is a formal EPO approval, which provides a patent protection until 2037.
The patent application, with application number no. 17711205.9, for which the EPO has issued an Intention to Grant notice, refers to the company’s lead investigational drug ROSgard as a product (“composition of matter”) and its medical use. The notice means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of ROSgard in Europe until 2037.
In addition to the Intention to Grant in Europe, Guard Therapeutics recently obtained approval of the corresponding patent in the US and Australia. The company has pending patent applications for ROSgard in several other major countries, including Japan, China, Canada and Brazil.
“With the EPO Intention to Grant notice in Europe, which follows the recent approval in the US for the corresponding patent, Guard Therapeutics has now obtained important patent protection for ROSgard in a large part of the global pharmaceutical market. We are happy for these successes in our continuous efforts to build value in our patent portfolio”, Tobias Agervald, CEO of Guard Therapeutics says.